PeptideLabs Logo
PeptideLabs
All profiles

Dulaglutide

Peptide · Metabolism & GLP-1

Promotes glucose-dependent insulin release and reduces the glucagon response when glucose is elevated.

Approved for specific uses
LibraryNo account · this device only

Also known as: GLP-1 · Trulicity

Use at a glance

Dulaglutide

Promotes glucose-dependent insulin release and reduces the glucagon response when glucose is elevated.

Which entry would you like to view?

Choose a source entry. Different products and study groups do not form one combined plan.

Medicine instructions · named product only

Product or source: Dulaglutide · TRULICITY

What amount?
0.75 mg
How often?
once per week
What time of day?
same weekday
In what setting?
entry
How is it used?
The named medicines are ready-made injectable solutions. Their instructions and device are product-specific.
Does it need mixing?
No. The named ready-made solutions are not mixed with water. A research powder is a different product.
View preparationCheck sources
Overview of all entries

  • Dulaglutide · entry

    Medicine instructions · named product only · TRULICITY

    0.75 mg · once per week · same weekday

  • Dulaglutide · At least 4 weeks per step

    Medicine instructions · named product only · TRULICITY

    1.5 mg · once per week · same weekday

  • Dulaglutide · At least 4 weeks per step

    Medicine instructions · named product only · TRULICITY

    +1.5 mg · ≤4.5 mg · once per week · same weekday

More factsPeptide · Metabolism & GLP-1
Classification
Peptide · Metabolism & GLP-1
Research focus
Promotes glucose-dependent insulin release and reduces the glucagon response when glucose is elevated.
Evidence
Established
Status
Approved for specific uses

Approved uses exist, but dose, formulation, device and monitoring are product- and indication-specific. A community table cannot replace the prescribing information or a prescription.

Schedule explained in detailApproved medicine

Amount status

Trulicity label for adults: 0.75 mg once weekly, increasing to 1.5 mg after at least four weeks; further 1.5 mg increments no sooner than every four weeks up to a maximum of 4.5 mg. The pediatric maximum is lower.

Profile evidence level: established.

Timing

Once weekly with the prefilled pen per the label.

No individual recommendation.

Cycle/duration

Long-term treatment for the approved T2D indication, no community cycle.

No individual recommendation.

Mixing & calculations

No. The named ready-made solutions are not mixed with water. A research powder is a different product.

All preparation informationProduct details and calculation examples from the available sources.

Trulicity is a single-use prefilled pen. No reconstitution and no BAC-water/U-100 conversion.

Reconstitution & quantitiesOpen basics, units and sources
Explained in very simple termsBefore reading any number: this page reports what a product label, study or online community states. It does not say what any person should use.

Amount

mg or µg describe the mass of a substance. That is not the same as ml of fluid or U on a syringe. The number is only the amount stated by the identified source.

Interval

The interval only describes the time stated between two points. For example, once every 7 days does not mean daily and never justifies catching up or doubling.

Cycle

A cycle is a stated period that may include breaks. A community cycle proves neither effectiveness nor safety and does not prevent long-term risks.

Reconstitution

Reconstitution means mixing powder with a defined volume of fluid. This changes concentration, not the total amount in the vial. On U-100, 100 U equals exactly 1 ml of volume.

Not a guide to misuse

All community figures are shown only to place widely circulated online protocols in context. They are not instructions for self-use, injection, performance enhancement or any other misuse. Approved figures apply only to the exact named product, approved indication and medical supervision.

Research, risks & more detailsMechanism, adverse effects, storage, comparisons and common questions.

Mechanism: what is supported and what does not follow

Long-acting GLP-1 receptor agonist

Dulaglutide is classified as “Long-acting GLP-1 receptor agonist”. Promotes glucose-dependent insulin release and reduces the glucagon response when glucose is elevated. This describes the investigated pathway but does not validate a community use, amount, route or combination.

01

GLP-1 receptor activation

Researchers study how activating the GLP-1 receptor affects fullness, stomach emptying, and insulin release after a meal. They typically measure blood sugar curves, body weight, and food intake over time, similar to tracking how quickly someone feels hungry again after eating.

02

Blood sugar and appetite outcomes

Researchers study how a substance changes blood sugar levels and feelings of hunger over the course of a day, similar to tracking how full someone feels after different meals. Typical measures include blood glucose readings and questionnaires about hunger and food intake.

03

Body weight and metabolism

Researchers track changes in body weight, body composition, and metabolic markers such as blood sugar or cholesterol over the course of a study. This is similar to following someone's weight and lab values over months to see broader trends rather than day-to-day fluctuations.

What communities discuss

These themes describe discussions and vendor claims. They do not prove benefit, safety, product identity or suitable use.

Weight management forums

In these forums, users compare their own weight trajectories, side effects, and perceived appetite changes between different products. Before-and-after photos and personal timelines are often shared. Such anecdotes and vendor marketing claims are not scientific proof of efficacy.

General wellness forums

Broader wellbeing impressions such as mood, sleep, and general feeling after using various products are exchanged here, usually without structured tracking. Such general impressions are not a substitute for targeted clinical examination.

Source and purity discussion

Discussion covers which vendors are seen as more trustworthy and how purity test results differ between batches. Such community assessments are based on limited samples and do not replace independent lab testing of each individual batch.

Adverse effects and safety risks

  • Gastrointestinal effects, dehydration, and changes in glucose or appetite may occur depending on the target; incretin medicines can also carry gallbladder, pancreatic and retinopathy warnings.
  • Local reaction, infection, abscess and contamination are possible with any injection that is not professionally manufactured and administered.
  • A label or clear appearance does not exclude unknown purity, wrong identity, endotoxins or concentration errors.

Do not self-use / obtain clinical review

  • Pregnancy, severe gastric-emptying disorders, and relevant pancreatic, gallbladder, renal or endocrine disease require professional assessment; the exact label may add contraindications.
  • Acute symptoms, allergic reaction, breathing difficulty, chest pain, neurological deficits or severe abdominal pain require immediate medical care.
  • Children and adolescents, pregnancy/breastfeeding, and people with relevant disease should not be part of unsupervised experiments.

Monitoring and laboratory markers

  • Depending on substance and indication, weight, blood pressure, hydration, glucose/HbA1c, kidney and liver markers, and concomitant medicines may be reviewed; symptoms guide further tests.
  • Baseline, objective, measurement timing and stop criteria must be defined professionally in advance. Individual laboratory values cannot compensate for unknown product quality.

Evidence boundary

Established

Efficacy is documented in approval trials; individual response rates still differ.

Clinical evidence

The described biological role is well established, or extensive regulator-reviewed human data exist for clearly defined products and uses. This does not automatically transfer to other products or purposes.

Dulaglutide is a long-acting GLP-1 agonist, distinct from shorter-acting agents such as exenatide.

Storage and stability

  • Per the label, store at 2–8 °C, protected from light and do not freeze.
  • A single pen may be kept for up to 14 days at no more than 30 °C; check the specific label.

Troubleshooting and common errors

  • U-100 units measure volume, not drug amount: 100 U equals 1 mL. A wrong concentration makes every unit figure wrong.
  • Do not shake or dilute further to ‘fix’ cloudiness, particles or uncertain solubility; discard and obtain professional clarification.
  • Do not calculate a double or extra amount to compensate for missed use or an uncertain injection.
  • Without a COA, clear supplier, correct label and consistent vial information, identity is not confirmed.

Regulatory status and WADA

Approved for specific uses

Prescription active ingredient for defined indications in at least one jurisdiction; not offered here.

WADA 2026

The atlas has no explicit WADA flag for this profile. That does not automatically mean every form, route or related class is permitted in sport.

WADA — 2026 Prohibited List

Combinations / stacks

  • Combinations change effects, adverse effects and laboratory values; evidence for one substance does not establish the safety of a stack.
  • Overlapping pathways may add up. Hormonal, glucose, blood-pressure, coagulation, immune and sedating effects are important potential interactions.
  • Non-standardised blends prevent separate dosing, cause attribution and dependable reconstitution.

Frequently asked questions

Is an amount shown here a recommendation?

No. This page separates approved product information, study protocols and community information. No number or calculator is an individual dosing recommendation.

Does the U-100 calculator prove correct use?

No. It only converts mass, volume and syringe scale. It cannot check identity, purity, sterility, stability, solvent or medical suitability.

Can this profile be combined with other substances?

Safety of a combination cannot be inferred from a single-substance profile. Overlapping pathways, medicines and undefined blends can increase risk.

Which source controls when information conflicts?

For approved medicines, the current prescribing information and treating professional control. For research substances, conflict shows that no dependable self-use standard exists.

Are community claims clinical evidence?

No. Anecdotes can generate questions but do not replace controlled studies, regulatory review, or identity and quality testing.

Back to all 64 profilesOpen scientific atlas profile